Abstract
In recent years in vivo chemical screening in zebrafish has emerged as a rapid and efficient method to identify lead compounds that modulate specific biological processes. By performing primary screening in vivo, the bioactivity, toxicity, and off-target side effects are determined from the onset of drug development. A recent study demonstrates that in vivo screening can be used successfully to perform structure-activity relationship (SAR) studies. This work validates the zebrafish as an effective model for not only drug discovery but also drug optimization.
Original language | English (US) |
---|---|
Pages (from-to) | 159-161 |
Number of pages | 3 |
Journal | ACS Chemical Biology |
Volume | 5 |
Issue number | 2 |
DOIs | |
State | Published - Feb 19 2010 |
Externally published | Yes |
ASJC Scopus subject areas
- Biochemistry
- Molecular Medicine